摘要
目的观察沙格列汀联合门冬胰岛素30注射液(BIAsp30)治疗老年2型糖尿病的疗效及安全性。方法将84例既往口服降糖药物血糖控制不佳的老年2型糖尿病患者随机分为2组,试验组口服沙格列汀5 mg每日1次,并联合注射BIAsp30每日2次治疗;对照组仅注射BIAsp30每日2次,共治疗12周。观察2组患者服药后各项指标的变化。结果治疗后,2组糖化血红蛋白(HbA1c)、空腹血糖(FBG)和餐后2 h血糖(2hBG)均显著降低(均P<0.05),与对照组比较,试验组的2hBG下降幅度更大(P<0.05),且试验组的胰岛素用量、低血糖发生率、体重指数(BMI)均较对照组明显下降(均P<0.05)。结论沙格列汀联合BIAsp30可显著改善老年2型糖尿病患者的血糖控制水平,尤其是餐后血糖;同时可以减少胰岛素用量,减轻体重及使低血糖风险降低。
Objective To study the safety and efficacy of saxagliptin combined with insulin aspart 30 injection （ BIAsp30 ） in the treatment of elderly patients with type 2 diabetes（ T2Db）.Methods The 84 elderly patients with T2Db mellitus inadequately controlled with oral antidiabetic drugs were randomly divided into 2 groups with 12 weeks of treatment.The patients in the trial group were given oral saxagliptin 5 mg once a day, combined with BIAsp30 insulin injections twice a day.The patients in the control group only were given BIAsp 30 insulin injections twice a day.The items were investigated in two groups after administration.Results After treatment, the fasting blood glucose （FBG）, postprandial 2 h b1ood glucose （2hBG）, and hemoglobin Alc（HbA1c） were signifi-cantly lower than that before treatment in two groups （ all P〈0.05 ） . Compared with the control group , 2hBG level in trial group was signifi-cantly decreased （ P〈0.05 ）.Dosage of insulin , incidence of hypogly-caemia and body mass index （ BMI ） in trial group were significantly re-duced （ all P〈0.05 ）.Conclusion Saxagliptin combined with BIAsp 30 was found to be safe and effective to improve the glycaemia control in eld-erly patients with T2 Db , especially the 2 hBG level , and the drugs can reduce the dosage of insulin ,lose weight and decrease the risk of hypo-glycaemia for the T2Db mellitus patients.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第7期568-570,共3页
The Chinese Journal of Clinical Pharmacology
基金
新疆医科大学创新基金资助项目(XJC2012113)
关键词
老年2型糖尿病
沙格列汀
门冬胰岛素30注射液
糖化血红蛋白
空腹血糖
elderly patient with type 2 diabetes mellitus
saxagliptin
insulin aspart 30 injection
hemoglobin A1 c
fasting blood glucose
